{
    "clinical_study": {
        "@rank": "84128", 
        "arm_group": [
            {
                "arm_group_label": "trivalent inactivated  influenza", 
                "arm_group_type": "Active Comparator", 
                "description": "Intradermal injection"
            }, 
            {
                "arm_group_label": "trivalent inactivated influenza", 
                "arm_group_type": "Active Comparator", 
                "description": "Intramuscle injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, Open label randomized study. A total of 220 adults aged \u2265 60 years\n      will be enrolled and randomized to one of 2 study arms:\n\n        1. Seasonal inactivated intradermal influenza vaccine (15 \u03bcg HA per strain/ 0.1 ml dose)\n           (group A - 110 participants)\n\n        2. Seasonal inactivated intramuscular  influenza vaccine (15 \u03bcg  HA per strain/ 0.5 ml\n           dose) (group B - 110 participants) Groups A and B will receive the vaccine at day 1.\n           Total follow up period is 60 days."
        }, 
        "brief_title": "Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group.", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Immunization", 
            "Seasonal Influenza"
        ], 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "The consent form will be reviewed and signed by the participant prior to any study-related\n      procedures.\n\n      Potential study participants will be assessed based on inclusion and exclusion criteria.\n      Screening procedures, which include taking medical history, vital signs, random blood for\n      dextrostix and vaccination will be performed on day 1.\n\n      A total of 220 participants will be randomized into 2 study arms, of which each group of 110\n      vaccinees will receive either seasonal intradermal influenza vaccine [group A] or seasonal\n      intramuscular influenza vaccine [group B]. The randomization route of vaccination will be\n      kept in concealed envelope at the study site. It will be open after subject signed informed\n      consent form and all inclusion exclusion criteria met for enrollment. Groups A and B will\n      receive the vaccine at day 1. Clinical activities for groups A and B during each visit\n      (total of 5 visits). Blood will be drawn and assayed (for baseline assessment) using HAI to\n      the three influenza strains."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          -  Male or female aged \u2265 60 years\n\n          -  Healthy and/or medically stable with controlled chronic medical conditions (e.g.\n             diabetes mellitus, hypertension ) able to help oneself\n\n        Exclusion criteria\n\n          -  Known history of systemic hypersensitivity to egg or chicken proteins or any of the\n             vaccine components\n\n          -  Influenza infection within the past 3 months\n\n          -  History of Guillain Barre Syndrome (GBS) or brachial neuritis within 6 weeks of\n             previous influenza vaccination\n\n          -  Treatment with immunosuppressive or other immune-modifying drugs or cancer therapy\n             within the past 6 months\n\n          -  Any concomitant medication with aspirin\n\n          -  Participation in other intervention study\n\n          -  Incapacity to provide fully informed consent or be attentive to follow-up\n             observations resulting from cognitive impairment, abuse of alcohol or drug addiction\n\n          -  Random blood for Dextrostix more than 200 mg/dL"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101749", 
            "org_study_id": "Elderly Flu vaccine"
        }, 
        "intervention": {
            "arm_group_label": [
                "trivalent inactivated  influenza", 
                "trivalent inactivated influenza"
            ], 
            "description": "intradermal or intramuscular injection in the deltoid area.", 
            "intervention_name": "trivalent inactivated  influenza", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "trivalent inactivated  influenza vaccine", 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "contact": {
                "email": "punnee.pit@mahidol.ac.th", 
                "last_name": "Punnee Pitisuttithum", 
                "phone": "662-6445599"
            }, 
            "contact_backup": {
                "phone": "662-3549178"
            }, 
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10400"
                }, 
                "name": "Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University,"
            }, 
            "investigator": {
                "last_name": "Punnee Pitisuttithum", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparative Immune Response of Intradermal and Intramuscular Preparations of", 
        "other_outcome": {
            "description": "Exploratory objective to assess other related immune response (e.g. anti-neuraminidase)", 
            "measure": "Assess other related immune response", 
            "safety_issue": "No", 
            "time_frame": "60 days"
        }, 
        "overall_official": {
            "affiliation": "Mahidol University", 
            "last_name": "Punnee Pitisuttithum, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Vaccine is able to induce a 4-fold rise of Hemagglutination inhibitionin antibodies 70% of vaccinees within 60 days after vaccination (according to EMA and CBER guidelines)", 
            "measure": "Immunological end point", 
            "safety_issue": "No", 
            "time_frame": "with in 60 days post vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101749"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess safety of the following trivalent inactivated seasonal influenza vaccine in the older age group", 
            "measure": "To assess safety", 
            "safety_issue": "Yes", 
            "time_frame": "60 Days"
        }, 
        "source": "Mahidol University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mahidol University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}